Arena Pharmaceuticals Executive Officers

Investor Relations

Arena Pharmaceuticals
Executive Officers

Investor Relations

Corporate Profile

Arena is a clinical-stage biopharmaceutical company committed to discovering and developing innovative therapies offering significant medical advances and new options for patients. We are focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Our lead drug candidate, lorcaserin hydrochloride, is intended for the treatment of obesity and is being evaluated in a Phase 3 clinical trial program. Our broad pipeline of novel compounds target G protein-coupled receptors (GPCRs), an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc. and Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Featured Report

2007 Interactive Annual Report

Stock Information

Ticker ARNA Exchange NASDAQ
Last Price 4.85 Change 0.10 down
Open 4.87 Previous Close 4.95
Day High 4.89 Day Low 4.68
52-Week High 7.42 52-Week Low 2.26
Quotes delayed at least 20 minutes. Information provided by eSignal.

Events & Presentations

There are no upcoming events available at this time.

Receive Email Alerts

Click here to sign up for email alerts



The stock information, SEC filings and press releases included on this website are not provided by Arena Pharmaceuticals, Inc. but by a third-party. Such information is not intended for trading purposes. Arena Pharmaceuticals, Inc. does not guarantee the accuracy or completeness of this information and is not liable in any way whatsoever for any delays, inaccuracies, errors in, or omissions of any such information, or for any actions taken in reliance on this information, or for any damages arising there from.
---
Copyright 2007
Terms and Conditions | Privacy Statement
  Contact Us  Site Map |   Search